Allogene Therapeutics, Inc.
ALLOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 14, 2026 | Bernstein | $3.85(+26%) | $3.06 | TheFly | |
| Apr 14, 2026 | Robert W. Baird | $9.00(+194%) | $3.06 | TheFly | |
| May 16, 2024 | H.C. Wainwright | Debjit Chattopadhyay | $9.00(+202%) | $2.98 | StreetInsider |
| May 14, 2024 | B.Riley Financial | Kalpit Patel | $7.00(+141%) | $2.90 | StreetInsider |
| Jun 13, 2022 | Robert W. Baird | Jack Allen | $11.00(+13%) | $9.74 | Pulse 2.0 |
| Jan 3, 2022 | Guggenheim | Michael Schmidt | $35.00(+129%) | $15.29 | TheFly |
| Dec 3, 2021 | Canaccord Genuity | John Newman | $55.00(+212%) | $17.62 | TheFly |
| Oct 8, 2021 | Roth Capital | Anthony Butler | $35.00(+167%) | $13.13 | TheFly |
| Oct 8, 2021 | Bank of America Securities | Jason Gerberry | $32.00(+144%) | $13.13 | StreetInsider |
| Oct 8, 2021 | Oppenheimer | Mark Breidenbach | $40.00(+205%) | $13.13 | TheFly |
| Oct 8, 2021 | Jefferies | Biren Amin | $30.00(+128%) | $13.13 | StreetInsider |
| Sep 23, 2021 | Raymond James | Dane Leone | $36.00(+30%) | $27.64 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citizens | maintain | Market Outperform | Aug 17, 2026 |
| JP Morgan | upgrade | Underweight →Neutral | Apr 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2026 |
| Jefferies | maintain | Buy | Apr 15, 2026 |
| Bernstein | maintain | Market Perform | Apr 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 14, 2026 |
| Baird | maintain | Outperform | Apr 14, 2026 |
| Citizens | maintain | Market Outperform | Apr 14, 2026 |
| Argus Research | maintain | Market Perform | Apr 14, 2026 |
| Piper Sandler | maintain | Overweight | Mar 13, 2026 |
| Canaccord Genuity | maintain | Buy | Mar 13, 2026 |
| Citizens | upgrade | Market Perform →Market Outperform | Jan 9, 2026 |
| JP Morgan | downgrade | Neutral →Underweight | Oct 10, 2025 |
| JP Morgan | downgrade | Overweight →Neutral | Aug 4, 2025 |
| JMP Securities | maintain | Market Perform | Aug 4, 2025 |
| Oppenheimer | maintain | Outperform | Aug 1, 2025 |
| Citigroup | maintain | Buy | May 15, 2025 |
| Baird | maintain | Outperform | May 14, 2025 |
| Truist Securities | maintain | Buy | May 14, 2025 |
| Piper Sandler | maintain | Overweight | May 14, 2025 |
| RBC Capital | maintain | Outperform | May 14, 2025 |
| Oppenheimer | maintain | Outperform | May 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 19, 2025 |
| Citizens Capital Markets | upgrade | Market Perform →Market Outperform | Mar 14, 2025 |
| RBC Capital | maintain | Outperform | Mar 14, 2025 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.15 | $-0.15 | — | $2.5K |
| Aug 12, 2026 | $-0.13 | $-0.17 | $4.6M | $2.5K |
| May 13, 2026 | $-0.18 | $-0.19 | — | $2.2K |
| Mar 12, 2026 | $-0.17 | $-0.25 | — | $2.5K |
| Nov 6, 2025 | $-0.19 | $-0.23 | — | $1.8K |
| Aug 13, 2025 | $-0.23 | $-0.28 | — | — |
| May 13, 2025 | $-0.28 | $-0.28 | — | $1.7K |
| Mar 13, 2025 | $-0.28 | $-0.34 | $22.0K | $12.0K |
News
Allogene Therapeutics, Inc. ( ALLO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President, CEO & Director Geoffrey Parker Conference Call Participants Tyler Van Buren - TD Cowen, Research Division Michael Yee - UBS Investment Bank, Research Division Jiale Song - Jefferies LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Matthew Phipps - Wi…
Allogene Therapeutics NASDAQ: ALLO expects to complete enrollment in its ALPHA3 lymphoma trial by the end of 2027, as increased screening and activity in Asia-Pacific help support recruitment, executives said on the company's third-quarter earnings call.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2026.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona. The Company's participation includes two invited presentations and a preclinical poster showcasing the breadth and continued evolut…
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced two November investor events highlighting third quarter 2026 results and the first clinical update from its ALLO-329 autoimmune disease program.
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conferences in November and December 2026.
Bank of America Corp DE bought a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,187,320 shares of the company's stock, valued at approximately $6,630,000. Bank of America Corp
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Frazier Life Sciences Management L.P. boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 491.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,446,668 shares of the company's stock after acquiring an additional 18,650,000 shares during the quarter.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.
Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 281,949 shares of the company's stock, valued at approximately $586,000. Deutsche Bank AG owned about 0.08% of Allogene
Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 322,827 shares of the company's stock, valued at approximately $671,000. Connor Clark
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.
Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.
Bank of America Corp DE lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 111.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,134,473 shares of the company's stock after acquiring an additional 1,127,145
Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 25.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,201,655 shares of the company's stock after acquiring an additional 243,839 shares during the quarter. Dimensional Fund Advisors
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript